Microdystrophin gene transfer is currently one of the most promising therapeutic avenues in DMD based on using AAVs to transfer a shortened, but still functional, version of dystrophin to fit the AAV vector capacity.27 The gene discussed is DMD; the disease is Duchenne muscular dystrophy.